•  
  •  
  •  

Welcome to the Allergy and Immunology website, which is designed to help you navigate your way through your allergic and immunological concerns.

The Allergy and Immunology Awareness Program (AIAP) is an HMC based program dedicated to raising awareness and understanding about these conditions.

Here you can learn about some of the basics and most common conditions, stay updated on the latest news and scientific advances for allergies and primary immunodeficiencies.

These pages also aim to support parents of children who have one or more of these conditions. As such we have stories and activities for our younger patients in the kids’ corner.

Allergic/immunological conditions usually start in childhood and most of the time, carry on well into adulthood. Not only do they have clear physical effects on a person, but also social, emotional and psychological ones, due to the chronic nature of the majority of these diseases.

Advances in medicine have made it possible to manage these diseases through pharmaceuticals as well as healthier daily choices. Living and coping with what could be the long term use of medications and lifestyle adaptations, can be a journey. As such, the AIAP was born to guide you through that journey, to simplify and create easy access to relevant information from sources you can trust.

We hope that through the resources presented on this site, we are able to link you to the information you and your family need.

 
Dr. Mehdi Adeli
MD, FAAAAI, FACAAI, FAAP, A.B.A.I, A.B.P
Senior Consultant, Allergy & Immunology 
Assistant Professor, Weill Cornell Medicine-Qatar
Pediatrics Department,
Hamad Medical Corporation
Recommendations of the Allergy and Immunology Awareness Program in cooperation with the International Patient Organization for Primary Immundeficiencies IPOPI for Primary Immundeficiency patients PID on the epidemic of Covid 19.


  • In December 2019, a cluster of pneumonia cases was reported in Wuhan, China, linked to be caused by a novel coronavirus.
  • Human coronaviruses commonly cause mild to moderate illness in the general population. So, the main symptoms include fever, fatigue, dry cough and runny nose. Some patient also experience aches and pains, nasal congestion, sore throat and diarrhea. Approximately 80% of people recover from this disease without needing special treatment.
  • There is currently no data pointing to whether PID patients are actually at higher risk of more severe disease from COVID-19. However, it is believed that PID patients might be at higher risk for this infection or a more severe course of the disease. Thus, patients with PID need to take extra care to prevent from getting this infection.
  • Patients with PID living in areas of high prevalence should take every precaution and adhere to local, regional and national recommendations.
  • We advise prompt phone contact with a doctor if an infection is suspected.
  • Keep in mind that it is always essential to regularly continue to take the treatment for your PID.
  • For PID patients who are on Ig replacement therapy, there is no evidence to date that more frequent dosing of Ig will offer more protection. Whilst Ig replacement therapy provides protection against a range of infections, it does not guarantee immunity against coronavirus. For PID patients whose condition does not require being under regular Ig replacement therapy, there is no need to start Ig replacement therapy since no antibodies targeting COVID-19 is expected to be contained in the existing preparations.
  • For more information, please visit the following link: https://ipopi.org/ipopi-publishes-a-joint-statement-on-the-epidemics-of-covid19/